Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA Sonodynamic Therapy in Newly Diagnosed High-Grade Glioma
2023-509238-20-00Phase 2Completed
- Sponsor
- Universität Münster
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in high-grade glioma (HGG), glioblastoma (GBM), anaplastic astrocytoma (AA) and 1 more, sponsored by Universität Münster. Primary endpoint: Clinical safety and tolerability (adverse events). Started Nov 2024; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
high-grade glioma (HGG)glioblastoma (GBM)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on 2023-509238-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509238-20-00.